GSK vs. RVMD: GSK vs. Revolution Medicines Stock Comparison

Company Profile

GSK (GSK) and Revolution Medicines (RVMD) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GSK is classified in Pharmaceuticals while RVMD is classified in Biotechnology.

GSK (GSK) has more than two decades of public-market history since March 28, 1980, whereas Revolution Medicines (RVMD) listed on February 13, 2020 and has a much shorter record to draw on.

Revolution Medicines (RVMD) trades as ordinary local shares, while GSK (GSK) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Revolution Medicines (RVMD) has an aggressive beta of 1.42, indicating higher sensitivity to broad-market moves, while GSK (GSK) is defensive at 0.31 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Revolution Medicines (RVMD) reports a negative ROE of -93.56%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile GSK (GSK) reports 28.27%, ranking against industry peers normally.

GSK (GSK) at 12.97% retains a top-quartile share of revenue as profit, ahead of Revolution Medicines (RVMD) at 0.00%, which keeps about the industry-typical share.

Revolution Medicines (RVMD) reports a negative operating margin of -188.88%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile GSK (GSK) reports 32.14%, ranking against industry peers normally.

Profitability Metrics

Growth

Only one side can be read here: GSK (GSK) reports revenue growth of 4.11%, ranked against its industry; Revolution Medicines (RVMD) has no revenue growth figure this period.

Only one side can be read here: GSK (GSK) reports EPS growth of 123.15%, ranked against its industry; Revolution Medicines (RVMD) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Revolution Medicines (RVMD) at 8.36 keeps current ratio within its industry’s typical mid-range, while GSK (GSK) at 0.86 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for GSK.

Revolution Medicines (RVMD) at 0.50 carries an industry-typical debt-to-equity mix, while GSK (GSK) at 1.30 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Revolution Medicines (RVMD) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile GSK (GSK) reports a yield of 1.57%, ranking against industry peers normally.

Revolution Medicines (RVMD) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile GSK (GSK) reports a payout of 63.33%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: GSK (GSK) trades at 17.54 times trailing earnings, ranked against its peers, while Revolution Medicines (RVMD) has no P/E ratio this period.

GSK (GSK) at 3.01 sits in the cheaper P/S ratio quartile while Revolution Medicines (RVMD) at 210.51 prices above its industry range — a wide gap in sales valuation between them.

GSK (GSK) at 4.02 sits near its industry’s typical P/B ratio, while Revolution Medicines (RVMD) at 17.31 prices above its benchmark range — RVMD looks rich relative to book.

Valuation Metrics